Eligo Bioscience

Eligobiotics”, a new generation of antimicrobials that can be programmed to target bacteria based on their genome. Eligobiotics therefore provide a new approach to explore, understand and control bacterial ecosystems both in human and animals. They can notably be used to selectively eradicate harmful pathogens from the microbiome while sparing beneficial ones.
Company Growth (employees)
Type
Private
HQ
Paris, FR
Founded
2014
Size (employees)
9 (est)
Eligo Bioscience was founded in 2014 and is headquartered in Paris, FR

Eligo Bioscience Office Locations

Eligo Bioscience has an office in Paris
Paris, FR (HQ)
18 Rue du Dr Roux

Eligo Bioscience Data and Metrics

Summary Metrics

Founding Date

2014

Total Funding

$2.2 m

Latest funding size

$2.2 m

Time since last funding

about 2 years

Investors

Eligo Bioscience's latest funding round in July 2015 was reported to be $2.2 m. In total, Eligo Bioscience has raised $2.2 m

Traffic Overview of Eligo Bioscience

Eligo Bioscience Online and Social Media Presence

Eligo Bioscience News and Updates

Small World: 20+ Startups Attacking The Human Microbiome

The human microbiome is an ecosystem of trillions of microbes — some dangerous and some beneficial — living within the body. For the most part, they quietly help us digest our food, absorb nutrients, and fight off dangerous pathogens. However, … Continued

Eligo Bioscience Company Life and Culture

You may also be interested in